


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of ~~Compounds of the~~ formula I



in which

$R^2, R^4$  denote H, A, Hal, cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $OCF_3$ , OA, NHA,  $NA_2$ , or  $NH_2$ ,

$R^3, R^6$  denote  $(CH_2)_nHet$ ,  $(CH_2)_nAr$ ,

$R^6$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

$R^3$  is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,


$R^1$  denotes H or  $CO_2R^5$ ,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_n(R^5)Het$ ,  $(CH_2)_nCH=N-$

















Het,  $(\text{CH}_2)_n\text{OCOR}'$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OCF}_3$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{C}(\text{R}^5)\text{OCOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{R}')\text{CH}_2\text{COHet}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}')\text{CH}_2\text{OCOR}'$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$ ,  $\text{CH}=\text{CHCOOR}^5$ ,  $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$ ,  $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$ ,  
 $\text{CH}=\text{CHCH}_2\text{OR}^5$  or  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$ ,















$\text{R}^5$  denotes H or A















A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,















Het ~~denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,~~  
is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperaziny, 1-(4-cyclopentyl)piperaziny, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl, 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below











 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____

 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____
 _____	 _____

 <hr/>	 <hr/>
 <hr/>	 <hr/>
 <hr/>	 <hr/>
 <hr/>	 <hr/>
 <hr/>	 <hr/>
 <hr/>	 <hr/>
 <hr/>	 <hr/>

	
	
	
	 or

Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR<sup>5</sup>, OOCR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH, R<sup>2</sup> and R<sup>4</sup> do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers salts,  
~~enantiomers, racemates thereof or mixtures of enantiomers.~~

2. (Cancelled)


3. (Currently Amended) A compound ~~Compounds of the formula I~~ according to claim 1, in which R<sup>4</sup> denotes H, Hal, CN, A or NO<sub>2</sub>.

4. (Currently Amended) A compound ~~Compounds of the formula I~~ according to claim 1, in which R<sup>2</sup> denotes H or alkyl.






5. (Cancelled)

6. (Currently Amended) A compound ~~Compounds of the formula I~~ according to claim 1, in which X has the meaning N.

7. (Currently Amended) A compound of formula ~~Compounds of the formulae IA, IB, IC, ID, IE or and IF:~~









in which

$R^3$ ,  $R^4$ ,  $R^6$  and X have the meanings indicated for the compound of formula I in Claim 1.


8. (Currently Amended) A process for preparing a compound of claim 1, which  
is of Process for the preparation of compounds of the formula IA



in which  $R^3$ ,  $R^4$ ,  $R^6$ , X and A have the meaning indicated for the compound of formula I  
or a salt in Claim 1 or salts or solvates thereof,  
comprising reacting a compound of the formula II




or an acid-addition salt salts thereof,  
in which  $R^4$ ,  $R^6$  and X have the meanings indicated for the compound of formula I in Claim 1,  
with a compound of the formula III




in which A and  $R^3$  have the meanings indicated for the compound of formula I in Claim 1,

and/or converting a basic compound of the formula IA into one of its salts by treatment with an acid.

9. (Currently Amended) A process for preparing a compound of claim 1, which is of Process for the preparation of compounds of the formula IB




in which R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, X and A have the meaning indicated for the compound of formula I or a salt in Claim 1 or salts or solvates thereof,  
comprising reacting a compound of the formula II



or an acid-addition salt salts thereof,

in which R<sup>4</sup>, R<sup>6</sup> and X have the meanings indicated for the compound of formula I in Claim 1,  
with a compound of the formula IV



in which A and R<sup>3</sup> have the meanings indicated for the compound of formula I in Claim 1,

and/or converting a basic compound of the formula IB into one of its salts by treatment with an acid.

10. (Cancelled)

11. (Currently Amended) A method for treating or combating the ~~treatment or prophylaxis~~ of sleep disorders mediated by the binding of compounds to 5 HT receptors, comprising administering to a host in need thereof a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

12. (Cancelled)

13. (Previously Presented) A method according to claim 11, wherein the salt, enantiomer, racemate or enantiomer mixture has a 5-HT<sub>2A</sub> receptor-antagonistic action.


14. (Previously Presented) A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts, and a pharmaceutically acceptable carrier.

15. (Currently Amended) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 1 and/or one of its physiological acceptable salts into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Currently Amended) A method for treating or combating the ~~prophylaxis or treatment~~ of premenstrual syndrome, comprising administering to a host in need thereof a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

17. (Currently Amended) A compound ~~Compounds of the formula~~

I according to claim 1, in which Het ~~is~~ denotes one of the following radicals:



18. (Currently Amended) A method for treating or combating the ~~prophylaxis or treatment~~ of schizophrenia or depression, comprising administering to a host in need thereof a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

19. (New) A method for the *in vitro* inhibition of 5-HT<sub>2A</sub> receptor, comprising administering to said receptor a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

20. (New) A compound according to claim 1, in which R<sup>1</sup> denotes H or (CH<sub>2</sub>)<sub>n</sub>COHet, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR', (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)OCOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R')CH<sub>2</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R')CH<sub>2</sub>OCOR', (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCOOR<sup>5</sup>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup> or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,

21. (New) A compound according to claim 1, in which  $R^1$  denotes H or  $CO_2R^5$ ,  $COHet$ ,  $CHO$ ,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_n(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)OCOR^5$ ,  $(CH_2)_nN(R')CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ .

22. (New) A compound according to claim 1, in which  $R^1$  denotes H or  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_n(R^5)Het$ ,  $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)OCOR^5$ ,  $(CH_2)_nN(R')CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ .

23. (New) A compound according to claim 1 or a pharmaceutically acceptable salt thereof.